ADAC's (US) molecular coincidence detection (MCD) nears market
This article was originally published in Clinica
ADAC (US) expects to complete multicentre clinical trials of its molecular coincidence detection (MCD) system next year. The technology, which enables combined PET and SPECT imaging on a single dual-function system, provides improved diagnostic imaging and reduces the cost of patient care, says ADAC. The MCD system will be added to the company's Vertex Epic and Solus Epic nuclear medicine imaging systems.